CLINICAL AND BIOMARKER REMISSION IS MAINTAINED AFTER SWITCH FROM MONTHLY DOSED VEDOLIZUMAB TO THE NOVEL SUBCUTANEOUS FORMULATION IN INFLAMMATORY BOWEL DISEASE
Špela Pintar 1
Jurij Hanzel 1
Natasa Smrekar 1
Matic Koželj 1
David Drobne 1
Tina Kurent 1
Borut Stabuc 1
Gregor Novak 1
1 University Medical Centre Ljubljana, Ljubljana, Slovenia
Conference
UEG Week 2022
Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]